Improved neuronal transgene expression from an AAV-2 vector with a hybrid CMV enhancer/PDGF-β promoter

Journal of Gene Medicine

Volumn 7, Issue 7, 2005, Pages 945-955

  Wang, C Y ^a   Guo, H Y ^a   Lim, T M ^a   Ng, Y K ^a   Neo, H P ^a   Hwang, P Y K ^a   Yee, W C ^a   Wang, S ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Adeno associated virus; CMV enhancer; Gene expression; Neuron; PDGF beta promoter

Indexed keywords

GENE PRODUCT; IMMEDIATE EARLY PROTEIN; PARVOVIRUS VECTOR; PLATELET DERIVED GROWTH FACTOR B;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SPECIFICITY; CONTROLLED STUDY; CORPUS STRIATUM; CYTOMEGALOVIRUS; DOPAMINERGIC NERVE CELL; EMBRYO; ENHANCER REGION; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; HYBRID; MALE; NERVE CELL; NERVE CELL CULTURE; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; RAT; SUBSTANTIA NIGRA; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELLS, CULTURED; CYTOMEGALOVIRUS; DEPENDOVIRUS; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION; GENETIC VECTORS; HUMANS; MALE; NEURONS; PLATELET-DERIVED GROWTH FACTOR; PROMOTER REGIONS (GENETICS); RATS; RATS, WISTAR; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA; TRANSFECTION; TRANSGENES;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS 2; CUCUMBER MOSAIC VIRUS; HUMAN HERPESVIRUS 5;

EID: 22544453919     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.742     Document Type: Article

References (42)

1. Peel AL, Klein RL. Adeno-associated virus vectors: activity and applications in the CNS. J Neurosci Methods 2000; 98: 95-104.
2. During MJ. Adeno-associated virus as a gene delivery system. Adv Drug Deliv Rev 1997; 27: 83-94.
3. Flotte TR, Afione SA, Zeitlin PL. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 1994; 11: 517-521.
4. Nakai H, Yant SR, Strom TA, Fuess S, Meuse L, Kay MA. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 2001; 75: 6969-6976.
5. Lai CM, Lai YK, Rakoczy PE. Adenovirus and adeno-associated virus vectors. DNA Cell Biol 2002; 21: 895-913.
6. Loser P, Jennings GS, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J Virol 1998; 72: 180-190.
7. Prosch S, Stein J, Staak K, Liebenthal C, Volk HD, Kruger DH. Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Biol Chem Hoppe Seyler 1996; 377: 195-201.
8. Dressel U, Renkawitz R, Baniahmad A. Promoter specific sensitivity to inhibition of histone deacetylases: implications for hormonal gene control, cellular differentiation and cancer. Anticancer Res 2000; 20: 1017-1022.
9. Fitzsimons HL, Bland RJ, During MJ. Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain. Methods 2002; 28: 227-236.
10. Sasahara M, Fries JW, Raines EW, et al. PDGF B-chain in neurons of the central nervous system, posterior pituitary, and in a transgenic model. Cell 1991; 64: 217-227.
11. Liu BH, Wang X, Ma YX, Wang S. CMV enhancer/human PDGF-β promoter for neuron-specific transgene expression. Gene Ther 2004; 11: 52-60.
12. Lyer M, Wu L, Carey M, Wang Y, Smallwood A, Gambhir SS. Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci U S A 2001; 98: 14 595-14 600.
13. Veelken H, Leutgeb B, Kulmburg P, Fiebig HH, Mackensen A, Lindemann A. Enhancement of a constitutively active promoter for gene therapy by a positive feed-back transcriptional activator mechanism. Int J Mol Med 1998; 2: 423-428.
14. Wang J, Yao M, Zhang Z, et al. Enhanced suicide gene therapy by chimeric tumor-specific promoter based on HSF1 transcriptional regulation. FEBS Lett 2003; 546: 315-320.
15. Ionescu AM, Drissi H, Schwarz EM, et al. CREB cooperates with BMP-stimulated Smad signaling to enhance transcription of the Smad6 promoter. J Cell Physiol 2004; 198: 428-440.
16. Nettelbeck DM, Jerome V, Muller R. A strategy for enhancing the transcriptional activity of weak cell type-specific promoters. Gene Ther 1998; 5: 1656-1664.
17. Robinson D, Elliott JF, Cheng LJ. Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels and is up-regulated by HIV-1 tat. Gene Ther 1995; 2: 269-278.
18. Sawicki JA, Morris RJ, Monks B, Sakai K, Miyazaki J. A composite CMV-IE enhancer/beta-actin promoter is ubiquitously expressed in mouse cutaneous epithelium. Exp Cell Res 1998; 244: 367-369.
19. Yew NS, Przybylska M, Ziegler RJ, Liu D, Cheng SH. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. Mol Ther 2001; 4: 75-82.
20. Xu LF, Daly T, Gao CH, et al. CMV-β-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1α promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther 2001; 12: 563-573.
21. Miller N, Whelan J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum Gene Ther 1997; 8: 803-815.
22. Paterna JC, Moccetti T, Mora A, Feldon J, Bueler H. Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Ther 2000; 7: 1304-1311.
23. Auricchio A, Hildinger M, O'Connor E, Gao GP, Wilson JM. Isolation of highly infectious and pure adeno-associated virus type 2 vector with a single-step gravity-flow column. Hum Gene Ther 2001; 12: 71-76.
24. Grimm D, Kern A, Pawlita M, Ferrari FK, Samulski RJ, Kleinschmidt JA. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther 1999; 6: 1322-1330.
25. Barnhart KM, Hartikka J, Manthorpe M, Norman J, Hobart P. Enhancer and promoter chimeras in plasmids designed for intramuscular injection: a comparative in vivo and in vitro study. Hum Gene Ther 1998; 9: 2545-2553.
26. Hagstrom JN, Couto LB, Scallan C, et al. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter. Blood 2000; 95: 2536-2542.
27. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193-199.
28. Kobayashi M, Tanaka A, Hayashi Y, Shimamura S. The CMV enhancer stimulates expression of foreign genes from the human EF-1 alpha promoter. Anal Biochem 1997; 247: 179-181.
29. Khachigian LM, Resnick N, Gimbrone MA JR, Collins TJ. Nuclear factor-kappa B interacts functionally with the platelet-derived growth factor B-chain shear-stress response element in vascular endothelial cells exposed to fluid shear stress. J Clin Invest 1995; 96: 1169-1175.
30. Rafty LA, Khachigian LM. Zinc finger transcription factors mediate high constitutive platelet-derived growth factor-B expression in smooth muscle cells derived from aortae of newborn rats. J Biol Chem 1998; 273: 5758-5764.
31. Hwang DY, Carlezon WA Jr, Isacson O, Kim KS. A high-efficiency synthetic promoter that drives transgene expression selectively in noradrenergic neurons. Hum Gene Ther 2001; 12: 1731-1740.
32. Kaspar BK, Erickson D, Schaffer D, Hinh L, Gage FH, Peterson DA. Targeted retrograde gene delivery for neuronal protection. Mol Ther 2002; 5: 50-56.
33. Mccown TJ, Xiao X, Li J, Breese GR, Samulski RJ. Differential and persistent expression pattern of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 1996; 713: 99-107.
34. Lo WD, Qu G, Sferra TJ, Clark R, Chen R, Johnson PR. Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum Gene Ther 1999; 10: 201-213.
35. Mastakov MY, Baer K, Xu R, Fitzsimons H, During MJ. Combined injection of rAAV with mannitol enhances gene expression in the rat brain. Mol Ther 2001; 3: 225-232.
36. Donello JE, Loeb JE, Hope TJ. Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 1998; 72: 5085-5092.
37. Xu R, Janson CG, Mastakov M, et al. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther 2001; 8: 1323-1332.
38. Philip R, Brunette E, Kilinski L, et al. Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes. Mol Cell Biol 1994; 14: 2411-2418.
39. Duan D, Sharma P, Yang J, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 1998; 72: 8568-8577.
40. Vieweg J, Boczkowski D, Roberson KM, et al. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 1995; 55: 2366-2372.
41. Hsiao CD, Hsieh FJ, Tsai HJ. Enhanced expression and stable transmission of transgenes flanked by inverted terminal repeats from adeno-associated virus in zebrafish. Dev Dyn 2001; 220: 323-336.
42. Kugler S, Lingor P, Scholl U, Zolotukhin S, Bahr M. Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. Virology 2003; 311: 89-95.